Setmelanotide治疗POMC或LEPR缺陷所致严重肥胖的疗效与安全性
两项单臂、开放标签、多中心3期试验评估MC4R激动剂setmelanotide在POMC或LEPR缺陷所致严重肥胖患者中的疗效与安全性。POMC试验中80%患者和LEPR试验中45%患者达到至少10%体重减轻,最饥饿评分显著下降,常见不良事件为注射部位反应和色素沉着。
要点
- Setmelanotide可显著降低POMC或LEPR缺陷肥胖患者体重
- 常见不良事件为注射部位反应和色素沉着,无严重治疗相关不良事件
核心结论
- 结果支持setmelanotide用于治疗POMC或LEPR缺陷引起的肥胖和食欲过盛。
研究设计与样本
- 两项单臂、开放标签、多中心3期试验在加拿大、美国、比利时、法国、德国、荷兰和英国的十家医院进行。
- POMC试验纳入10例,LEPR试验纳入11例6岁及以上POMC或LEPR缺陷肥胖患者,接受开放标签setmelanotide治疗12周。
- 体重减轻至少5 kg(或基线体重<100 kg者≥5%)者进入8周安慰剂对照撤药序列,随后再接受32周开放标签治疗。
主要发现
- POMC试验中8例(80%)患者和LEPR试验中5例(45%)患者在约1年时达到至少10%体重减轻。
- POMC试验所有10例患者报告注射部位反应和色素沉着;LEPR试验所有11例报告注射部位反应,5例报告皮肤疾病,4例报告恶心。
- 两项试验均无严重治疗相关不良事件发生。
关键数值与推荐
- 主要终点为约1年时体重较基线减轻至少10%的参与者比例,在改良意向治疗人群(至少接受一剂研究药物且有基线评估)中评估。
临床怎么用
- 对于POMC或LEPR缺陷所致严重肥胖和食欲过盛患者,setmelanotide可作为治疗选择。
- 治疗期间需监测注射部位反应、色素沉着、恶心和呕吐等不良事件。
局限性
- 两项试验均为单臂、开放标签设计,样本量小(POMC试验10例,LEPR试验11例)。
- 缺乏与安慰剂或标准治疗的平行对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The melanocortin 4 receptor (MC4R), a component of the leptin-melanocortin pathway, plays a part in bodyweight regulation. Severe early-onset obesity can be caused by biallelic variants in genes that affect the MC4R pathway. We report the results from trials of the MC4R agonist setmelanotide in individuals with severe obesity due to either pro-opiomelanocortin (POMC) deficiency obesity or leptin receptor (LEPR) deficiency obesity. METHODS: These single-arm, open-label, multicentre, phase 3 trials were done in ten hospitals across Canada, the USA, Belgium, France, Germany, the Netherlands, and the UK. Participants aged 6 years or older with POMC or LEPR deficiency obesity received open-label setmelanotide for 12 weeks. Participants with at least 5 kg weight loss (or ≥5% if weighing <100 kg at baseline) entered an 8-week placebo-controlled withdrawal sequence (including 4 weeks each of blinded setmelanotide and placebo treatment) followed by 32 additional weeks of open-label treatment. The primary endpoint, which was assessed in participants who received at least one dose of study medication and had a baseline assessment (full analysis set), was the proportion of participants with at least 10% weight loss compared with baseline at approximately 1 year. A key secondary endpoint was mean percentage change in the most hunger score of the 11-point Likert-type scale at approximately 1 year on the therapeutic dose, which was assessed in a subset of participants aged 12 years or older in the full analysis set who demonstrated at least 5 kg weight loss (or ≥5% in paediatric participants if baseline bodyweight was <100 kg) over the 12-week open-label treatment phase and subsequently proceeded into the placebo-controlled withdrawal sequence, regardless of later disposition. These studies are registered with ClinicalTrials.gov, NCT02896192 and NCT03287960. FINDINGS: Between Feb 14, 2017, and Sept 7, 2018, ten participants were enrolled in the POMC trial and 11 participants were enrolled in the LEPR trial, and included in the full analysis and safety sets. Eight (80%) participants in the POMC trial and five (45%) participants in the LEPR trial achieved at least 10% weight loss at approximately 1 year. The mean percentage change in the most hunger score was -27·1% (n=7; 90% CI -40·6 to -15·0; p=0·0005) in the POMC trial and -43·7% (n=7; -54·8 to -29·1; p<0·0001) in the LEPR trial. The most common adverse events were injection site reaction and hyperpigmentation, which were reported in all ten participants in the POMC trial; nausea was reported in five participants and vomiting in three participants. In the LEPR trial, the most commonly reported treatment-related adverse events were injection site reaction in all 11 participants, skin disorders in five participants, and nausea in four participants. No serious treatment-related adverse events occurred in both trials. INTERPRETATION: Our results support setmelanotide for the treatment of obesity and hyperphagia caused by POMC or LEPR deficiency. FUNDING: Rhythm Pharmaceuticals.
引用
- Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020. PMID: 33137293. doi:10.1016/S2213-8587(20)30364-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。